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ABSTRACT
Background Leber’s hereditary optic neuropathy
(LHON) and a multiple sclerosis (MS)-like illness appear
to coexist 50 times more frequently than would be
expected by chance. This association of LHON and MS
(LMS) raises an important question about whether there
could be a common pathophysiological mechanism
involving mitochondrial dysfunction.
Objective The primary aim was to deﬁne MRI features
of LMS and LHON, and to assess the proportions of
individuals displaying features typical of MS. Secondarily,
we investigated the effect of gender on the risk of
developing white matter lesions in the context of LHON.
Methods A blinded standardised review of
conventional brain MRIs of 30 patients with MS, 31
patients with LHON and 11 patients with LMS was
conducted by three independent experts in the ﬁeld.
MS-like MRI features were assessed.
Results All patients with LMS and 26% of patients
with LHON had white matter lesions. Of these, all
patients with LMS and 25% with LHON were found to
have an MRI appearance typical of MS. Female patients
with LHON had a signiﬁcantly greater risk of having
white matter lesions consistent with MS compared with
male patients (relative risk 8.3).
Conclusions A blinded review of conventional brain
MRIs shows that patients with LMS have a scan
appearance indistinguishable from MS. Mitochondrial
dysfunction could be a common pathophysiological
pathway in the formation of white matter lesions. There
appears to be a strong female inﬂuence on the
radiological appearance as well as clinical development
of MS in patients with LHON.
INTRODUCTION
Leber’s hereditary optic neuropathy (LHON) is a
maternally inherited mitochondrial condition that
manifests as painless subacute bilateral visual loss
usually in early adulthood. It is caused by DNA point
mutations at sites 3460, 11778 and 14484 that
encode complex 1 of the respiratory chain. A mul-
tiple sclerosis (MS)-like disease in association with
LHON (LMS) is very rare but coexists about 50
times more frequently than expected by chance.1–4
This may suggest that mitochondrial disturbance is
important in the pathophysiology of MS.
The association between LHON and MS was
ﬁrst described by Lees et al5 in 1964. A larger case
series was published by Harding et al,1 and
reported 11 patients with LHON and MS. 6 Thus,
the association is often referred to as ‘Harding’s
disease’. Although LHON shows a far greater pene-
trance in men (approximately 77% of cases),7 only
a third of the patients with Harding’s disease are
men.2 It has been theorised that when the high
threshold for clinical expression in women with
Leber’s mutations is crossed, MS pathology may be
triggered.2
MS is associated with distinctive MRI features.8
Therefore, if the imaging characteristics of Harding’s
disease are indistinguishable from those of MS, this
would provide further support for a common patho-
physiological mechanism. Of note, a previous report
of two cases of Harding’s disease suggested that there
are important differences,9 with reduced brightness
and indistinct margins of T2 lesions and a lack of T1
hypointensity on MRIs. However, other patients
with more typical appearances have also been
reported in the literature.6 10
The objectives of this study were to assess
whether the MRI appearances of patients with
Harding’s disease (LMS) differ from those with
relapsing remitting MS, to characterise cerebral
MRI ﬁndings in LHON and, more speciﬁcally, to
determine whether female patients with LHON are
more likely to have brain MS-like lesions than male
patients.
METHODS
Data collection
Brain MRIs were retrospectively obtained from six
sites (Oxford, Milan, Siena, London, Bochum and
Copenhagen) from patients with clinical LHON
with or without a relapsing MS-like illness, and
patients with age-matched relapsing MS for com-
parison. Thirty-one patients with LHON and 11
with an MS-like illness (LMS) were identiﬁed, and
30 MS controls were selected. Participant
characteristics are summarised in table 1.
Patients with MS and LMS required two or more
relapses disseminated in time and space. All
patients with LHON and LMS had a conﬁrmed
genetic mutation. Patients with LMS were diag-
nosed locally in MS specialist centres and had clin-
ical histories consistent with MS. Patients with
LHON had been scanned either routinely or for
research purposes. The imaging data for each
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participant included good quality 1.5 Tesla transverse
T2-weighted and unenhanced T1-weighted brain images as a
minimum. Participants with a neurological disease that would
change the appearance of the brain MRI were excluded. All the
ﬁve patients with LMS for whom we had the results of cerebro-
spinal ﬂuid examination were positive for unmatched oligoclo-
nal bands.
All the MRI and clinical data sets were ﬁrst collated, anon-
ymised and stored at the contributing sites in accordance with
the local research ethics regulations.
Scan collation and scoring
The imaging and clinical data were collated centrally in
Oxford, quality controlled and blinded (by LM). The brain
MRIs for all participants were then independently reviewed
by three experts in the ﬁeld of MRI and MS (FF, CE and
AR), blinded to clinical and demographic data. The scoring
criteria had been preagreed by the Magnetic Resonance
Imaging in MS (MAGNIMS) collaborative group and required
the reviewers to ﬁrst comment on whether the scans were
normal or abnormal, and then to document the features of
the scan including the location, symmetry, morphology,
border and size of T2 lesions. T1 hypointense lesion
characteristics were also recorded including their presence,
size and location. The presence of brain atrophy was assessed
by visual inspection (ie, quantitative volumetric analysis was
not performed). The expert reviewers were then asked to
comment on whether they considered MRI as being consist-
ent with MS. The questionnaire is provided in the online
supplementary material as eFigure 1.
Data analysis
The results of the questionnaires were compiled and unblinded.
The inter-rater agreement between the three independent
reviewers was calculated using Fleiss’ κ.
An adapted version of the 2010 revision to McDonald’s MRI
criteria regarding ‘dissemination in space’, to take into account
the lack of spinal cord imaging, was applied to each partici-
pant’s brain MRI. This criterion is the presence of at least one
T2 lesion in two of three locations (periventricular, juxtacortical
or infratentorial) and is based on the work of Swanton et al.11
RESULTS
All patients with MS and LMS and 8 of 31 of
those with LHON had T2 hyperintense white matter lesions
(table 2).
The inter-rater agreement for whether a scan was considered
to be typical of MS was high at 94%, κ=0.88, p<0.001. MRIs
of 27 of 30 (90%) patients with MS were rated as consistent
with MS by all three reviewers. Two of the three non-consistent
MS scans had complete agreement and one was rated as such by
two of the three reviewers. These three patients had a relatively
benign clinical course of MS with two relapses only. Two of 8
(25%) abnormal MRIs in patients with LHON were consistent
with MS as shown in table 3. All the patients with LMS were
thought to have scans consistent with MS by at least two of the
three reviewers.
The characteristics of the lesions were similar in patients
with MS and LMS but patients with LHON and T2 hyperin-
tense white matter lesions had notably less oval lesions and
no Dawson’s ﬁngers or diffuse type lesions (ie, ill-deﬁned
widespread lesions; ﬁgure 1A). Seven of eight patients
with LHON had small lesions between 2 and 5 mm in
size, and one had a lesion of 15 mm. The patients with LMS
and MS generally had larger lesions ranging from 2 to
25 mm.
T2 lesions (ﬁgure 1B) had a similar distribution in MS and
LMS, whereas in the LHON group there were proportionally
fewer lesions in the corpus callosum and none in the cerebellum.
T1 hypointensity was found in the majority of patients with
MS and LMS (table 2), but only in three of the eight patients
with LHON and an abnormal MRI. Brain MRIs with features
of atrophy were similarly common in patients with MS and
LMS (table 2).
Figure 2 shows some illustrative brain MRIs of patients with
LMS and LHON with T2 hyperintense white matter lesions.
A detailed overview of the patients with LHON and LMS is
shown in table 3.
In total, 90% of patients with MS, 6.7% of patients with
LHON and 73% of patients with LMS fulﬁlled McDonald’s
criterion for the dissemination of brain lesions in space, as spe-
ciﬁed in the Methods section. There were no clear differences
in lesion location or morphology between genetic mutations.
However, the number of patients with 3460G and 14484T
mutations was relatively small. There were no remarkable com-
ments in the ‘other comments’ section of the scoring
questionnaire.
Of the 12 women in total with LHON, 8 had LMS and 3
had asymptomatic T2 hyperintense white matter lesions. Of the
30 men in total with LHON, 3 had LMS and 5 had asymptom-
atic T2 hyperintense white matter lesions. None of the scans of
the ﬁve men with LHON alone but two of the three women
with LHON with T2 hyperintense white matter lesions were
felt to be MS consistent (and one reviewer scored the remaining
women as being consistent). Thus, the increased relative risk of
women with LHON having white matter lesions typical of MS
was 8.3 (95% CI 2.8 to 25.1, p<0.01).
Table 2 Summary of results
LHON LMS MS
Total 31 11 30
T2 lesions 8 (26%) 11 (100%) 30 (100%)
T1 hypointense lesions 4 (13%) 9 (82%) 23 (77%)
Brain atrophy 4 (13%) 5 (45%) 13 (43%)
MRI consistent with MS as judged by at
least two of three raters
2 (6.5%) 11 (100%) 27 (90%)
Modified McDonald’s dissemination in
space criteria
2 (6.5%) 8 (73%) 30 (100%)
LHON, Leber’s hereditary optic neuropathy; LMS, MS-like disease in association with
LHON; MS, multiple sclerosis.
Table 1 Participant characteristics
LHON LMS MS
Number 31 11 30
Age at time of MRI, years, range 19–50 33–61 22–65
Sex 27M/4F 3M/8F 10M/20F
Genetic mutation m.3460G>A 3 1 NA
m.11778G>A 23 8 NA
m.14484T>C 5 2 NA
LHON, Leber’s hereditary optic neuropathy; LMS, MS-like disease in association with
LHON; MS, multiple sclerosis; NA, not applicable; WMLs, white matter lesions visible
on T2 MRI.
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DISCUSSION
The ﬁndings of our study suggest that conventional MRI
characteristics of MS and LMS lesions are indistinguishable to
the expert eye. The morphology and location of cerebral
lesions are similar, and T1 hypointense lesions and brain
atrophy exist in both conditions, supporting the idea that the
MRI changes in LMS are due to MS pathology and not a sep-
arate Leber’s mitochondrial-related process. This is further
backed by the observation that the majority of males with
LHON without an MS-like illness had either normal brain
MRIs or non-speciﬁc white matter lesions. In addition, our
data support a strong inﬂuence of female gender on develop-
ing MS and on having radiological appearances of MS in indi-
viduals with LHON alone despite LHON being more
common in men.
In accordance with LMS having MS pathology is the fact that
the extraoptic MS-like disease that affects patients with LHON
has the same clinical features with relapses that remit and sec-
ondary progression.1 2 5 Additionally, a single postmortem case
report of a patient with LMS found features of MS pathology
with demyelinated plaques as well as mitochondrial damage.12
The female predisposition is also similar in MS and LMS
despite LHON being predominant in men.
Previous reports of the MRI appearances gave conﬂicting
results. A case series of two patients commented on features
atypical of MS.9 They noted that their periventricular T2
lesions were either larger (>20 mm) or smaller (<5 mm) than
typical Dawson’s ﬁngers, and that there were lesions with indis-
tinct margins. T1 hypointense lesions and contrast enhance-
ment were not found in these two cases. Features more typical
of MS have been reported by Harding et al1 in a case series of
ﬁve patients. Additionally, a quantitative MRI study of patients
with LHON found abnormalities of the normal-appearing
brain tissue consistent with that previously reported in MS.10 It
is possible that the non-MS-like features reported by some
studies might either be due to the Leber’s mitochondrial path-
ology coexisting or these mitochondrial defects inﬂuencing the
MS appearances.
A hypothesis as to why LHON may be a risk factor for MS
is that mitochondrial defects trigger the autoimmune process.
A further possibility is that mitochondrial dysfunction is a ﬁnal
common pathway in neural damage. There is an increasing
body of work that suggests that mitochondrial dysfunction
with subsequent energy failure is important in MS lesion for-
mation,13 14 axonal damage15 16 and neurodegeneration.17
There is also some evidence that variation in mitochondrial
DNA and nuclear-encoded mitochondrial genes may affect
genetic susceptibility to MS.18 However, there does not appear
to be a speciﬁc mitochondrial mutation (as found in LHON)
or deletion in cases of MS with apparent maternal
inheritance.19
Two studies have shown that MS and clinical LHON occur
more frequently than expected by chance. The ﬁrst by
Vanopdenbosch et al3 identiﬁed ﬁve patients with MS from a
LHON pedigree study of 103 patients. A second paper reported
5 from 29 patients with LHON who had an MS-like illness.4 In
contrast, a recent third study concluded that these conditions
did not occur more frequently than expected by chance.
However, there were a number of reasons why the authors may
have reached an erroneous conclusion.20 The background preva-
lence of MS quoted was extremely high and was in fact a future
20–40-year projected value.21 The authors also did not distin-
guish between the higher rate of LHON mutations versus clin-
ical LHON; penetrance is only 50% in men and 14% in
women.7 In addition, this study used a voluntary surveillance
reporting scheme, which is not an accepted method of preva-
lence calculation, and not all the patients reported to them were
included. Their estimated expected concurrence rates were
therefore markedly overestimated, and the observed rates
underestimated.
Table 3 Patients with LHON with white matter lesions
Diagnosis Sex Age Genetic mutation
Number of relapses
(increased optic neuritis)
Number of T2 white matter
lesions on MRI
MRI consistent with
MS
Rater
1 2 3
LMS M 42 14484 >2 19 Y Y N
LMS F 41 11778 >2 >20 with confluence Y Y Y
LMS M 36 11778 >2 1 (Confluent) Y Y Y
LMS M 45 11778 >2 3 Y Y Y
LMS F 61 11778 >2 2 Y N Y
LMS F 36 11778 3 with secondary progression >20 Y Y Y
LMS F 50 3460 4 1 (Confluent) Y Y Y
LMS F 34 11484 3 with secondary progression 12 Y Y Y
LMS F 48 11778 4 2 Y N Y
LMS F 33 11778 2 >20 Y Y Y
LMS F 32 11778 2 >15 Y Y Y
LHON F 33 3460 NA 12 Y Y Y
LHON F 41 11778 NA >20 Y Y Y
LHON F 46 11778 NA 3 N N Y
LHON M 40 11778 NA 2 N N N
LHON M 50 11778 NA 8 N N N
LHON M 22 11778 NA 4 N N N
LHON M 68 11778 NA 6 N N N
LHON M 25 11778 NA 10 N N N
LHON, Leber’s hereditary optic neuropathy; LMS, MS-like disease in association with LHON; MS, multiple sclerosis.
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The inﬂuence of gender is intriguing. The penetrance of
LHON in women is much lower than in men.7 20 However, it
appears that once a woman develops LHON clinically, she has
a very high risk of developing either radiological or clinical
MS. It is not clear whether those with asymptomatic lesions
at the time of MRI will develop clinical features in the future,
nor what the risk is in asymptomatic female carriers of
Leber’s mutation.
The limitations of this study include the small numbers of
patients with LMS because of its rarity. Also, we did not use
quantitative analysis tools to assess MRIs because they were not
obtained in a standardised manner and were collected from
many different sources. However, the expert reviewers all have
extensive experience in MS MRI analysis and there was excel-
lent agreement between their scoring. It was not possible to
blind the experts to the presence of optic neuropathy in MRIs;
however, this would not have aided them in distinguishing
between LHON and LMS. The scan protocols did not include
high resolution or fat saturated images of the optic nerves.
Owing to the retrospective nature of the data collection,
gadolinium-enhanced MRI was also not available for many par-
ticipants, and therefore not assessed. This would be an interest-
ing area of future study.
We note that more LMS patients were felt to have MRIs typical
of MS than fulﬁlled the revised McDonald criteria for dissemin-
ation in space. This is because the experts were asked to judge
whether the scan was ‘compatible with’ rather than diagnostic of
MS. This assessment therefore included other features of MS such
as highly suggestive lesion morphology including Dawson’s ﬁngers
or juxtacortical curved u-ﬁbre lesions.
Figure 1 Bar graphs showing (A) morphology of T2 lesions in each participant group (B) lesion location in each participant group. LHON, Leber’s
hereditary optic neuropathy; LMS, MS-like disease in association with LHON; MS, multiple sclerosis.
Multiple sclerosis
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This is the ﬁrst blinded observational study of the MRI features
of LHON and LMS. It demonstrates similar conventional brain
MRI appearances in MS and LMS. Our study supports the notion
that mitochondrial pathways may be important in the develop-
ment of MS and also demonstrates that being female in association
with having LHON confers one of the highest identiﬁed risks for
MS. It also highlights that MRI should always be used in the
context of the clinical picture when making the diagnosis of MS,
and that rarer overlap disorders should be considered. Further
work on gender and mitochondrial inﬂuences is required.
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